<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03306836</url>
  </required_header>
  <id_info>
    <org_study_id>2016YFC1301800-2</org_study_id>
    <nct_id>NCT03306836</nct_id>
  </id_info>
  <brief_title>Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 2</brief_title>
  <acronym>EAPCAAMHO2</acronym>
  <official_title>Multi-center，Single Blind，Prospective Randomized Controlled Trial of Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kunming Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanjing PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Medical University Union Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the stage of randomized controlled study, our purpose is to obtain the Intraoperative
      anticoagulation program supported by evidence-based medicine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is divided into anticoagulation program in cerebral aneurysm with hybrid operation
      and anticoagulation program in cerebral arteriovenous malformations with hybrid operation two
      parts, and each part divide into two stage, on the stage of registration study. This study is
      a multi-center, single-blind, prospective cohort study. Record the patient's intraoperative
      activated coagulation time Changes in detail, to observe the effect of activated coagulation
      time maintenance level on hemorrhage event rate of Intraoperative and postoperative 48 hours,
      purpose to find out the safety range of activated coagulation time level in cerebral aneurysm
      and arteriovenous malformations with hybrid operation. On the stage of randomized controlled
      study. This study is a multicenter, single-blind, prospective, randomized controlled study.
      Patients is divided into intraoperative standard dose group of Heparin Sodium and low dose
      group of Heparin Sodium randomly. To observe the effect of different anticoagulation regimens
      on activated coagulation time safety coverage rate during surgery, and finally develop a
      scientific and effective intraoperative anticoagulant therapy program.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in activated coagulation time safety coverage rate from the beginning of surgery to 48 hours after surgery</measure>
    <time_frame>From the beginning of surgery to 48 hours after surgery</time_frame>
    <description>Activated coagulation time average value falls in the safety coverage rate from the beginning of surgery to 48 hours after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in hemorrhage event rate from the beginning of surgery to 48 hours after surgery</measure>
    <time_frame>From the beginning of surgery to 48 hours after surgery</time_frame>
    <description>Hemorrhage event include intracranial hemorrhage caused by non-surgical reasons, as well as other organs or parts of the massive bleeding or small bleeding, Including subperitoneal hemorrhage, intraocular hemorrhage, gross hematuria, epistaxis time prolonged or repeated, gastrointestinal bleeding, hemoptysis, subconjunctival hemorrhage, hematoma greater than 5cm, bleeding difficult to control the and so on.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ischemia event rate from the beginning of surgery to 48 hours after surgery</measure>
    <time_frame>From the beginning of surgery to 48 hours after surgery</time_frame>
    <description>Ischemia event include Cerebral infarction and transient ischemic attack.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative blood loss</measure>
    <time_frame>From the beginning of surgery to 48 hours after surgery</time_frame>
    <description>All the blood lost during the surgery should be collected and measured.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">408</enrollment>
  <condition>Cerebral Aneurysm</condition>
  <condition>Arteriovenous Malformations</condition>
  <arm_group>
    <arm_group_label>Standard dose group of Heparin Sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First infused with 5000 IU of Heparin Sodium, then continuous infusion at a rate of 18 IU / kg.h during the hybrid operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose group of Heparin Sodium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>infusion Heparin Sodium at a rate of 18 IU / kg.h during the hybrid operation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin Sodium</intervention_name>
    <description>Infused with 5000 IU of Heparin Sodium</description>
    <arm_group_label>Standard dose group of Heparin Sodium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin Sodium</intervention_name>
    <description>Infusion Heparin Sodium at a rate of 18 IU / kg.h</description>
    <arm_group_label>Standard dose group of Heparin Sodium</arm_group_label>
    <arm_group_label>Low dose group of Heparin Sodium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.All patients undergoing hybird surgery.

        Exclusion Criteria:

          1. Poor general condition , severe primary disease, surgical contraindications

          2. Patient or family refused surgery

          3. Fusiform aneurysm,Traumatic aneurysm,Infectious aneurysms

          4. Combined with other hemorrhagic cerebrovascular disease

          5. Combined with malignant brain tumor

          6. Perinatal, Pregnancy

          7. Patients unwilling to participate in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yong Cao, Doctor</last_name>
    <phone>010-67096510</phone>
    <email>caoyong6@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Cao, M.D.</last_name>
      <phone>010-67096523</phone>
      <phone_ext>100050</phone_ext>
      <email>caoyong6@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Yong Cao, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2017</study_first_submitted>
  <study_first_submitted_qc>October 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2017</study_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Yong Cao</investigator_full_name>
    <investigator_title>principal</investigator_title>
  </responsible_party>
  <keyword>Hybrid operation</keyword>
  <keyword>Cerebral Aneurysm</keyword>
  <keyword>Arteriovenous Malformations</keyword>
  <keyword>Anticoagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Arteriovenous Malformations</mesh_term>
    <mesh_term>Hemangioma</mesh_term>
    <mesh_term>Intracranial Aneurysm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

